News Releases News Releases HOME HOME

August 8, 2002

New Pabron Ace Granule Launched
Contains Three Set of Special Ingredients

Pabron Ace Granule image

Taisho Pharmaceutical Co., Ltd. (President: Akira Uehara) put on sale a new version of its comprehensive cold medication Pabron Ace Granule on August 19.

The new Pabron Ace Granule’s three set of special ingredients—bromohexine hydrochloride, ibuprofen, and lysozyme chloride—target four hard-to-bear cold symptoms: sore throat, cough, fever, and runny or stuffy nose. The new product is a granular version of the Pabron Ace tablets put on sale in January.

Since Taisho Pharmaceutical’s launch of Pabron cough medicine in 1927, the company has continually expanded the Pabron line, developing new products and reformulating existing products to meet consumer demand for comprehensive cold relief. Consumers can be divided into those who purchase cold medication regularly and those who buy it as needed. While Taisho Pharmaceutical’s Pabron S Gold is positioned as basic stand-by, a cold medication for every member of the family, Pabron Ace is positioned as an adult cold remedy. Together, these products are the pillars of a strategy that provides consumers with comprehensive relief from the suffering caused by colds.

Principle Product Features
1. Ten active ingredients, including three new set of special ingredients.
2. Easy to swallow granular type.
3. Comprehensive cold relief for adults (age 15 and over)

Product Specifications
Name Pabron Ace Granule
Suggested Retail Price
6-pack package 1,380 yen
10-pack package 1,980 yen
14-pack package 2,480 yen
Active Ingredients (per 1.3g pack dose)
Ibuprofen 150 mg
Bromohexine hydrochloride 4 mg
Dihydrocodeine phosphate 8 mg
Noscapin 16 mg
dl-Methylephedrine hydrochloride 20 mg
Lysozyme chloride 30 mg (potency)
Carbinoxamine maleate 2.5 mg
Caffeine anhydride 25 mg
Thiamine nitrate (Vitamin B1 nitrate) 8 mg
Vitamin B2 4 mg
Indications For the relief of cold symptoms (sore throat, cough, fever, runny nose, stuffy nose, sneezing, postnasal drip, headache, chills, joint pain).
Dosage For persons 15 years of age and over, three doses per day, one pack per dose.
Date of Release August 19, 2002
Expected sales 3.0 billion yen in the first year.